ClinicalTrials.gg

Program

sunvozertinib

Also written as “DZD9008”, “Sunvozertinib” and “DZD9008+AZD4205”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Lymphoma, B-Cell, led by Dizal Pharmaceuticals.

Furthest: phase 3, since Dec 20, 202212 company-led studies, 5 open or runningNext primary completion: Sep 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dizal Pharmaceuticals125 open or runningphase 3since Dec 20, 2022May 21, 2019Sep 2029phase 3 · NCT07182682

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 21, 2019First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03974022 · 315 enrolled · United States, Argentina, Australia and more
  2. Oct 28, 2019Phase 2 study in Lymphoma, B-CellNCT04148742 · China
  3. May 13, 2021Phase 1 study in Healthy VolunteersNCT04909242 · 78 enrolled · United States
  4. Nov 22, 2021Phase 1 study in Healthy VolunteersNCT05159895 · 8 enrolled · United States
  5. May 28, 2022Phase 1 study in Healthy SubjectsNCT05418582 · 40 enrolled · United States
  6. Dec 20, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05668988 · 324 enrolled · United States, Argentina, Australia and more
  7. Jan 12, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05712902 · 104 enrolled · China
  8. Jun 22, 2023Phase 1 study in Carcinoma, Non-Small-Cell LungNCT05926180 · 25 enrolled · China
  9. Sep 6, 2023Phase 1 study in Hepatic ImpairmentNCT06084104 · 17 enrolled · United States
  10. Feb 7, 20242 phase 2 studies in Carcinoma, Non-Small-Cell LungNCT06295432, NCT06276283
  11. Sep 3, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07182682 · 360 planned · China

Ahead

  1. Sep 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07182682

TargetBeta

EGFR →ERBB2 →read by rule
“An orally available, irreversible, dual kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) that shows similar activity against certain activating mutations, including exon 20 insertions (exon20ins), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
sevabertinibruleBayerphase 38
enozertinibruleoric-pharmaceuticalsphase 23
EGFR/HER2 Mutant-selective Inhibitor BH-30643ruleblossomhill-therapeuticsphase 21
GENSCI139ruleChangchun GeneScience Pharmaceuticalphase 11

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07182682Carcinoma, Non-Small-Cell Lung · China3RecruitingSep 2029360
NCT06295432Carcinoma, Non-Small-Cell Lung · China2CompletedJun 8, 202630
NCT06276283Carcinoma, Non-Small-Cell Lung · China2RecruitingDec 31, 202560
NCT06084104Hepatic Impairment · United States1CompletedJun 12, 202417
NCT05926180Carcinoma, Non-Small-Cell Lung · China1CompletedMay 16, 202425
NCT05712902Carcinoma, Non-Small-Cell Lung · China2Active, not recruitingOct 17, 2022104
NCT05668988Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingJan 16, 2026324
NCT05418582Healthy Subjects · United States1CompletedJun 1, 202240
NCT05159895Healthy Volunteers · United States1CompletedMar 30, 20228
NCT04909242Healthy Volunteers · United States1CompletedFeb 7, 202278
NCT04148742Lymphoma, B-Cell · China2WithdrawnJul 20230
NCT03974022Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more2Active, not recruitingJul 29, 2024315

How it is read

Names in the registry

  • “DZD9008”, 6 entries
  • “sunvozertinib”, 2 entries
  • “Sunvozertinib”, 2 entries
  • “DZD9008+AZD4205”, 1 entry
  • “DZD9008 plus Bevacizumab”, 1 entry

Codes read as this program: DZD9008.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.